ATE421092T1 - Verwendung von gfap zum nachweis von intrazerebraler blutung - Google Patents

Verwendung von gfap zum nachweis von intrazerebraler blutung

Info

Publication number
ATE421092T1
ATE421092T1 AT04765563T AT04765563T ATE421092T1 AT E421092 T1 ATE421092 T1 AT E421092T1 AT 04765563 T AT04765563 T AT 04765563T AT 04765563 T AT04765563 T AT 04765563T AT E421092 T1 ATE421092 T1 AT E421092T1
Authority
AT
Austria
Prior art keywords
gfap
intracerebral hemorrhage
detecting
early
marker
Prior art date
Application number
AT04765563T
Other languages
English (en)
Inventor
Matthias Sitzer
Christian Foerch
Ingo Curdt
Original Assignee
Hoffmann La Roche
Matthias Sitzer
Christian Foerch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Matthias Sitzer, Christian Foerch filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE421092T1 publication Critical patent/ATE421092T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Prostheses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04765563T 2003-09-24 2004-09-24 Verwendung von gfap zum nachweis von intrazerebraler blutung ATE421092T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03021571A EP1519194A1 (de) 2003-09-24 2003-09-24 Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung

Publications (1)

Publication Number Publication Date
ATE421092T1 true ATE421092T1 (de) 2009-01-15

Family

ID=34178487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765563T ATE421092T1 (de) 2003-09-24 2004-09-24 Verwendung von gfap zum nachweis von intrazerebraler blutung

Country Status (6)

Country Link
US (3) US20060240480A1 (de)
EP (2) EP1519194A1 (de)
AT (1) ATE421092T1 (de)
DE (1) DE602004019120D1 (de)
ES (1) ES2319299T3 (de)
WO (1) WO2005029087A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519194A1 (de) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP2143735A1 (de) * 2008-07-10 2010-01-13 Institut Pasteur Variable Domänen von Schwerketten-Antikörpern, die sich gegen GFAPs richten
ES2665245T3 (es) * 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
EP3355059A3 (de) * 2009-06-19 2018-09-26 Banyan Biomarkers, Inc. Biomarker-assay eines neurologischen zustands
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
EP2628013B1 (de) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarker für gehirnverletzungen
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
US20130266963A1 (en) * 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
CN102353787B (zh) * 2011-09-27 2013-03-06 山东莱博生物科技有限公司 一种半定量检测人血清中gfap浓度的胶体金试纸条的制备方法
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
CN104142404B (zh) * 2013-05-10 2016-10-05 深圳市安群生物工程有限公司 检测人gfap蛋白的荧光免疫层析试纸及其制备方法
GB201309928D0 (en) * 2013-06-04 2013-07-17 Randox Lab Ltd Method
EP3022322A4 (de) 2013-07-17 2017-05-17 The Johns Hopkins University Multiprotein-biomarkertest für den nachweis von hirnläsionen und ergebnis
EP3029466A1 (de) * 2014-12-03 2016-06-08 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Verfahren zur Unterscheidung eines ischämischen Schlaganfalls von einem hämorrhagischem Schlaganfall
WO2016088104A2 (en) 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
JP2018510359A (ja) 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
JP2019535015A (ja) * 2016-10-03 2019-12-05 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
GB201619823D0 (en) * 2016-11-23 2017-01-04 Randox Laboratories Ltd And Teoranta Randox GFAP accumulating stroke
CN109633171A (zh) * 2018-12-29 2019-04-16 上海八通生物科技股份有限公司 快速检测gfap的荧光免疫层析试纸条及其制备与应用
WO2021009074A1 (en) 2019-07-12 2021-01-21 Adx Neurosciences Nv Novel markers as early predictors of alzheimer's pathology
JP2023551542A (ja) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価
CN114624448B (zh) * 2022-03-18 2022-09-20 北京美联泰科生物技术有限公司 一种用于检测胶质纤维酸性蛋白的试剂盒
WO2024178194A1 (en) * 2023-02-22 2024-08-29 Nanosomix Inc. Assay and methods for use in the care and diagnosis of stroke patients
EP4716852A1 (de) * 2023-05-23 2026-04-01 Institut National de la Santé et de la Recherche Médicale Verfahren zur unterscheidung zwischen hämorrhagischem schlaganfall und ischämischem oder mimischem schlaganfall unter verwendung von tpa als biomarker

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
US4743542A (en) * 1985-04-11 1988-05-10 Ortho Diagnostic Method for forestalling the hook effect in a multi-ligand immunoassay system
GB8621261D0 (en) * 1986-09-03 1986-10-08 Barnard G J R Enhanced luminescent assay
US5733721A (en) * 1992-11-20 1998-03-31 The Board Of Regents Of The University Of Oklahoma Cell analysis method using quantitative fluorescence image analysis
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2001075165A2 (en) 2000-03-30 2001-10-11 Elan Pharmaceuticals, Inc. Screening markers and methods for neurodegenerative disorders
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1390497A2 (de) * 2001-05-25 2004-02-25 Genset Menschliche cdns und proteine und verwendungen davon
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
WO2003032894A2 (en) * 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
WO2003062824A1 (en) * 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
WO2004078204A1 (en) 2002-06-12 2004-09-16 The Cleveland Clinic Foundation Markers of blood barrier permeability and methods of using same
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DK2357477T3 (en) 2003-09-20 2018-02-05 Electrophoretics Ltd Diagnostic approach for brain injury-related disorders based on detection of NDKA
EP1519194A1 (de) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP2207033B1 (de) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neuralproteine als Biomarker für Verletzungen des Nervensystems und anderen neuralen Störungen
US7396689B2 (en) * 2005-02-04 2008-07-08 Decision Biomarkers Incorporated Method of adjusting the working range of a multi-analyte assay
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico

Also Published As

Publication number Publication date
ES2319299T3 (es) 2009-05-06
DE602004019120D1 (de) 2009-03-05
US10794918B2 (en) 2020-10-06
EP1668370B1 (de) 2009-01-14
EP1668370A1 (de) 2006-06-14
EP1519194A1 (de) 2005-03-30
US20060240480A1 (en) 2006-10-26
WO2005029087A1 (en) 2005-03-31
US20150247867A1 (en) 2015-09-03
US20210102958A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
ATE421092T1 (de) Verwendung von gfap zum nachweis von intrazerebraler blutung
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE428929T1 (de) Reagens, ausstattung und verfahren zur probenanalyse
CY1111229T1 (el) Μεθοδος προσδιορισμου ρευματοειδους αρθριτιδας με μετρηση αντι-ccp και ιντερλευκλινης 6
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE382861T1 (de) Universeller biosensor und verfahren zur verwendung
DE60310012D1 (de) Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
DE602005009925D1 (de) Verfahren zur beurteilung rheumatoider arthritis durch messen von anti-ccp und serumamyloid a
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
FR2895087B1 (fr) Methode de discrimination d'au moins deux populations cellulaires et application
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
ATE455297T1 (de) Mikrosensor zur bestimmung von d-aminosäuren
BRPI0704641A2 (pt) kit de teste rápido e método para detecção e localização de úlceras e outros sangramentos do trato digestivo em equinos utilizando anticorpos monoclonais e policlonais de hemoglobina e albumina equina
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
TW200502399A (en) Recombinant virus and use thereof and method of detecting an analyte in a sample and kit thereof
WO2010006616A3 (en) Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi)
ATE455305T1 (de) Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren
ATE403141T1 (de) Verfahren und vorrichtung zur messung rheologischer stoffeigenschaften einer visko- elastischen probe.
TH183243A (th) ชุดตรวจสอบความเป็นพิษโดยรวมและรูปแบบความเป็นพิษของสารตัวอย่าง จากแบคทีเรียและรีคอมบิแนนต์แบคทีเรีย และกรรมวิธีตรวจสอบ
BRPI0512611A (pt) métodos e composições para a detecção de moléculas biológicas empregando um complexo de duas partìculas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668370

Country of ref document: EP